Skip to content
Menu Close
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
Menu Close
  •  Global
    • India 
    • US 
    • Canada canada_flag
    • Europe   
    • Emerging Markets
      • Asia – Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  •  Global
    • India 
    • US 
    • Canada canada_flag
    • Europe   
    • Emerging Markets
      • Asia – Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  • Global

More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
Connect with Us
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS

Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination for Adults with Type 2 Diabetes having Comorbidities

  • Post author:glenmark2025
  • Post published:October 20, 2022
  • Post category:

Continue ReadingGlenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination for Adults with Type 2 Diabetes having Comorbidities

Glenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

  • Post author:glenmark2025
  • Post published:October 6, 2022
  • Post category:

Continue ReadingGlenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

  • Post author:glenmark2025
  • Post published:October 26, 2021
  • Post category:

Continue ReadingGlenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Glenmark launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler

  • Post author:glenmark2025
  • Post published:October 11, 2021
  • Post category:

Continue ReadingGlenmark launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler

Glenmark announces results of its “FAITH” combination trial

  • Post author:glenmark2025
  • Post published:October 21, 2020
  • Post category:

Continue ReadingGlenmark announces results of its “FAITH” combination trial

Glenmark introduces NINDANIB (Nintedanib) for the treatment of Pulmonary Fibrosis in India

  • Post author:glenmark2025
  • Post published:October 21, 2020
  • Post category:

Continue ReadingGlenmark introduces NINDANIB (Nintedanib) for the treatment of Pulmonary Fibrosis in India

Glenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg

  • Post author:glenmark2025
  • Post published:October 19, 2020
  • Post category:

Continue ReadingGlenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg

Glenmark receives ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg

  • Post author:glenmark2025
  • Post published:October 7, 2020
  • Post category:

Continue ReadingGlenmark receives ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg

Glenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 250 mg

  • Post author:glenmark2025
  • Post published:October 17, 2019
  • Post category:

Continue ReadingGlenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 250 mg

Glenmark Pharmaceuticals receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg

  • Post author:glenmark2025
  • Post published:October 9, 2019
  • Post category:

Continue ReadingGlenmark Pharmaceuticals receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg
  • Go to the previous page
  • 1
  • 2
  • 3
  • Go to the next page

Glenmark Pharmaceuticals Ltd. is a research‐led, global pharmaceutical company, having a presence across Branded, Innovative, and Generics segments with a focus on therapeutic areas of respiratory, dermatology and oncology

Linkedin-in Instagram Youtube

About us

  • Our Journey
  • Board of Directors
  • Leadership
  • Governance
  • Manufacturing
  • R&D

Innovation

  • Overview
  • Pipeline
  • Partnerships

Products

  • Portfolio
  • Top Brands

Responsibility

  • Corporate Social Responsibility
  • Sustainability

Investors

  • Financials
  • Disclosures under Regulation 46
    of SEBI LODR
  • Investor Resources
  • Other announcements

News

  • Press Release
  • Media Library

Careers

  • Life at Glenmark
  • Glenmark Centre for Learning
Join Us

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us

Download Factsheet
  • Privacy Portal
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
© 2026 Glenmark Pharmaceuticals Ltd. All Rights Reserved.
  • About Us
  • Innovation
  • Products
  • Responsibility
  • Investors
  • News
  • Careers
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
  • Privacy Portal
Download Factsheet
Linkedin-in Instagram Youtube
© 2026 Glenmark Pharmaceuticals Ltd.
All Rights Reserved.
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
Type your search

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us